Yep, just a repeat of the same stuff they they put out in 2010 at that presentation. Main difference now versus how funny iy was then is 3 years later, even much more competition in the Plavix area (including brand new technologies that can be used on sight and at low cost), information from ARYC that shows what PDx actually is based on (and that is just preliminary work mainly on some LRRK2 mutations versus PD), etc. But now it's all under AD and ARYC will own a limited amount of that. 60% and declining with every stock issuance at AD level. The amount of cash they need just to get through an FDA application on OvaDx is pretty overwhelming and something they haven't achieved.